Biocryst Pharmaceuticals price to sales ratio BCRX

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 2.1×
10-year median: 13.4×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.1× to 132×
Peer median: 6.8×

Biocryst Pharmaceuticals' price to sales ratio is 2.1× as of Oct 23, 2026.

That is below its ten-year median of 13.4×, lower than on 100% of days in the last ten years.

Over that time it ranged from 2.1× in Oct 2026 to 132× in Mar 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

median 13.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.1×	2.1×	3.0×
2025	2.7×	2.4×	4.6×
2024	3.9×	2.6×	4.7×
2023	3.9×	3.2×	9.2×
2022	9.0×	8.2×	29.6×
2021	21.9×	18.1×	132×
2020	24.6×	5.9×	38.3×
2019	29.1×	15.0×	48.9×
2018	39.6×	14.1×	47.0×
2017	16.0×	11.3×	24.9×
2016	21.2×	2.6×	23.5×
2015	15.4×	14.4×	68.7×
2014	46.1×	26.8×	65.6×
2013	40.8×	2.2×	40.8×
2012	2.6×	2.3×	8.8×

Against its peers

Companies in Biotechnology nearest Biocryst Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
BCRXBiocryst Pharmaceuticals	2.1×
VCELVericel	7.1×
ADMAAdma Biologics	4.7×
MGTXMeiraGTx	2.2×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
PLXProtalix BioTherapeutics	2.5×
Peer median	6.8×

Where Biocryst Pharmaceuticals ranks

#6of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Biocryst Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.